DWP 05195

Drug Profile

DWP 05195

Alternative Names: DWP-05195; TR-1

Latest Information Update: 07 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Analgesics
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuropathic pain

Most Recent Events

  • 10 Aug 2015 Phase II development is ongoing in South Korea
  • 26 Feb 2014 Phase-II development is ongoing in South Korea
  • 01 Dec 2013 Daewoong Pharmaceuticals completes a phase II trial in Neuropathic pain in South Korea (NCT01557010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top